Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 266.25 -2.7 (-1%) Market Cap: 34.34 Bil Enterprise Value: 33.21 Bil PE Ratio: 0 PB Ratio: 1,065.00 GF Score: 78/100

Alnylam Pharmaceuticals Inc Conference Call to Discuss FDA Approval of GIVLAARI (Givosiran) Transcript

Nov 20, 2019 / 07:15PM GMT
Release Date Price: $108.21 (+10.50%)
Operator

Ladies and gentlemen, thank you for standing by. Welcome to the Alnylam Pharmaceuticals conference call to discuss the FDA approval of GIVLAARI. There will be a question-and-answer session to follow. Please be advised that this call is being taped at the company's request. I would now like to turn the conference over to the company. Please go ahead.

Christine Regan Lindenboom
Alnylam Pharmaceuticals, Inc. - VP of IR & Communications

Good afternoon. I'm Christine Lindenboom, Vice President of Investor Relations and Corporate Communications at Alnylam. With me today on the phone are John Maraganore, Chief Executive Officer; Akshay Vaishnaw, President of R&D; and Barry Greene, President. In addition, Jeff Poulton, Chief Financial Officer; Andy Orth, Head of the U.S. business; and Akin Akinc, General Manager of the givosiran program, are in the room and available for Q&A. For those of you participating via conference call, the slides will be made available via webcast, can also be accessed by going to the Investor page of our website,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot